Nonetheless, several challenges persist, including CAR-T resistance mediated by CD19 downregulation, the diminished function of engineered lymphocytes due to prior treatments, and limited efficacy against the high disease tumor burden, and in the context of a heightened systemic inflammatory state, patients’ comorbidities and poor performance status, and logistical complexities. This evidence concerns the gene CD19 and neoplasm.